NeuroPace, Inc.
NASDAQ:NPCEMedical - Devices
+$0.05 today
- Market cap
- $283.19M
- Beta
- 1.88
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.64
Volume 0.31M
Average 0.18M
NPCE Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
NeuroPace, Inc.NASDAQ: NPCE
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $16.43M rose 9.2% year over year, behind the +17.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.2% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Selling, general & admin amounted to 65.7% of revenue in FY2025, down 5.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $76.58M (+16.6%) for the fiscal year ending Dec 2026, a step up from the +15.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.43M+7.2% QoQ
- Last fiscal yearDec 2025
- $65.67M+15.0% YoY
- LTMMar 2026
- $67.05M+17.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 65.67M USD
- Year-over-year change
- +15.0%
- 4-year CAGR
- +13.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.67M | +15.0% |
| FY2024 | 2024-12-31 | 57.1M | +4.7% |
| FY2023 | 2023-12-31 | 54.52M | +6.2% |
| FY2022 | 2022-12-31 | 51.34M | +31.8% |
| FY2021 | 2021-12-31 | 38.96M | — |
Selling, General & Admin vs competitors
How NPCE compares with its peers on the latest reported figures
- NPCE's LTM Mar 2026 selling, general & admin of $67.05M is the lowest of the 2 companies compared; the peer median is $88.81M.
- Its year-over-year change of +17.5% is the highest of 2, against a peer median of +5.3%.
- Selling, general & admin amounts to 67.4% of revenue for NPCE, versus a peer median of 150.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $88.81M | +5.3% | +20.9% | 150.3% | |
| LTM Mar 2026 | $67.05M | +17.5% | +8.6% | 67.4% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding NPCE) | $88.81M | +5.3% | +20.9% | 150.3% | |
Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.18M | 45.52M | 65.42M | 79.91M | 99.99M |
| Cost of Revenue | 11.75M | 13.03M | 17.3M | 20.82M | 22.77M |
| Gross Profit | 33.44M | 32.49M | 48.12M | 59.09M | 77.22M |
| Gross Margin | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Research & Development | 18.21M | 21.95M | 20.78M | 23.65M | 27.89M |
| Selling, General & Admin | 38.96M | 51.34M | 54.52M | 57.1M | 65.67M |
| Operating Expenses | 57.17M | 73.29M | 75.3M | 80.76M | 93.56M |
| Depreciation & Amortization | 296K | 2.99M | 1.61M | 1.77M | 1.95M |
| EBITDA | (28.37M) | (36.57M) | (22.83M) | (16.57M) | (12.06M) |
| EBITDA Margin | -62.8% | -80.3% | -34.9% | -20.7% | -12.1% |
| Operating Income | (23.74M) | (40.79M) | (27.17M) | (21.67M) | (16.34M) |
| Operating Margin | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Interest Income | 448K | 1.58M | 3.05M | 3.02M | 2.82M |
| Interest Expense | 7.41M | 7.53M | 8.52M | 8.8M | 7.46M |
| Other Income / Expenses | (12.34M) | (6.29M) | (5.78M) | (5.47M) | (5.13M) |
| Income Before Tax | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Pre-Tax Margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Net Margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| EPS (Basic) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
| EPS (Diluted) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
| Weighted Avg Shares | 16.61M | 24.59M | 25.85M | 29.13M | 32.72M |
| Weighted Avg Shares (Diluted) | 16.61M | 24.59M | 25.85M | 29.13M | 32.72M |
NeuroPace, Inc.
NASDAQ:NPCE
Intrinsic Alpha fair value
Locked
Current Price
$8.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.